FDA
-
-
-
-
-
-
-
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
-
-
-
-
-
-
-
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
-
-
-
-
-
-
-
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
-
-
-
-
-
-
-
Ligand Pharma (LGND) Leads $75 Million Royalty Financing in Castle Creek Biosciences
-
-
-
-
-
-
-
Ligand Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Ligand Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
322,978 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

